Spondyloarthropathies News

There are no clinically relevant differences in treatment retention among patients receiving biosimilar or originator biologic disease-modifying antirheumatic drugs as first exposure to that drug, data published in Rheumatology show.

Bimekizumab demonstrates statistically significant improvement over placebo in the proportion of patients achieving Assessment of Spondyloarthritis International Society 40 response at week 16, according to interim results released by UCB.

Just 0.7% of fully vaccinated patients with inflammatory rheumatic and musculoskeletal disease experience a breakthrough COVID-19 infection, while only 4.4% demonstrate disease flare reactions, according to data.

In October, Boehringer Ingelheim’s adalimumab-adbm secured a landmark FDA approval as the first interchangeable biosimilar to AbbVie’s blockbuster drug, Humira — but, as rivals scramble for second place, will the designation be worth the price?

Few randomized clinical trials support using repository corticotropin injection for most FDA-approved indications, including rheumatoid arthritis, ankylosing spondylitis, lupus, optic neuritis and nephrotic syndrome, according to researchers.

The FDA has approved the seventh biosimilar to adalimumab, adalimumab-aqvh, for all eligible indications of the biologic product, the latest in an increasingly crowded biosimilar logjam set to release in 2023.

Patients with self-reported elevated spine symptoms in psoriatic arthritis, with or without a diagnosis of axial disease, had worse quality of life and disease activity overall versus patients without axial manifestations, according to data.

The FDA has approved Xeljanz for the treatment of adults with active ankylosing spondylitis who have had an inadequate response, or intolerance to, TNF inhibitors, according to a Pfizer press release.

In patients with non-radiographic axial spondyloarthritis, MRI sacroiliitis and HLA-B27 positivity, but not elevated C-reactive protein or responses at week 12, predict long-term certolizumab pegol response, according to data.

The COVID-19 pandemic brought with it a significant decrease in autoimmunity laboratory testing, first rheumatology visits and diagnoses from 2019 to 2020, according to Italian data published in The Journal of Rheumatology.